|1.||Sherris, David: 7 articles (06/2014 - 11/2008)|
|2.||Marampon, Francesco: 2 articles (06/2014 - 08/2011)|
|3.||Tombolini, Vincenzo: 2 articles (06/2014 - 08/2011)|
|4.||Jannini, Emmanuele A: 2 articles (06/2014 - 08/2011)|
|5.||Festuccia, Claudio: 2 articles (06/2014 - 08/2011)|
|6.||Gravina, Giovanni Luca: 2 articles (06/2014 - 08/2011)|
|7.||Beijnen, Jos H: 2 articles (09/2013 - 12/2011)|
|8.||Lin, Fan: 2 articles (09/2013 - 12/2011)|
|9.||Sherris, D: 2 articles (05/2011 - 03/2009)|
|10.||Vittorini, Francesca: 1 article (06/2014)|
|1.||Prostatic Neoplasms (Prostate Cancer)
03/24/2009 - "This study describes the antitumour activity of the novel Akt inhibitor 8-(1-Hydroxy-ethyl)-2-methoxy-3-(4-methoxy-benzyloxy)-benzo[c]chromen-6-one (Palomid 529 or P529) as well as its ability to decrease radiation-activated phospho-Akt (p-Akt) signalling in a prostate cancer model. "
06/01/2014 - "Torc1/Torc2 inhibitor, Palomid 529, enhances radiation response modulating CRM1-mediated survivin function and delaying DNA repair in prostate cancer models."
03/24/2009 - "The novel Akt inhibitor Palomid 529 (P529) enhances the effect of radiotherapy in prostate cancer."
08/01/2011 - "The TORC1/TORC2 inhibitor, Palomid 529, reduces tumor growth and sensitizes to docetaxel and cisplatin in aggressive and hormone-refractory prostate cancer cells."
12/15/2011 - "Palomid 529 (8-(1-Hydroxy-ethyl)-2-methoxy-3-(4-methoxy-benzyloxy)-benzo[c]chromen-6-one), is a novel non-steroidal small-molecule drug, which inhibits both mTORC1 and mTORC2 assembly, and elicits both anti-angiogenic and direct anti-tumor effects in vivo. "
12/15/2011 - "High-performance liquid chromatography analysis of a novel small-molecule, anti-cancer drug, Palomid 529, in human and mouse plasma and in mouse tissue homogenates."
11/15/2008 - "We present a novel PI3K/Akt/mTOR inhibitor, Palomid 529 (P529), which inhibits the TORC1 and TORC2 complexes and shows both inhibition of Akt signaling and mTOR signaling similarly in tumor and vasculature. "
11/15/2008 - "Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeability."
05/26/2011 - "The third generation inhibitor of mammalian target of rapamycin (mTOR), Palomid 529, significantly suppressed Brca1-deficient tumor growth in mice through inhibition of both Akt and mTOR signaling. "
|3.||Retinal Detachment (Retinal Detachments)
|4.||Macular Degeneration (Age-Related Maculopathy)
12/01/2013 - "Subconjunctival Palomid 529 in the treatment of neovascular age-related macular degeneration."
12/01/2013 - "In this 12-week phase I open-label prospective pilot study, five participants with neovascular age-related macular degeneration that were refractory to intravitreal anti-vascular endothelial growth factor (VEGF) received three serial monthly subconjunctival doses of 1.9 mg Palomid 529. "
|2.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|6.||Adenosine Triphosphate (ATP)